Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis.

Simón Serrano S, Grönberg A, Longato L, Rombouts K, Kuo J, Gregory M, Moss S, Elmér E, Mazza G, Gallay P, Pinzani M, Hansson MJ, Massoumi R.

Cells. 2019 Nov 8;8(11). pii: E1409. doi: 10.3390/cells8111409.

3.

Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis.

Kuo J, Serrano SS, Grönberg A, Massoumi R, Hansson MJ, Gallay P.

Front Pharmacol. 2019 Sep 26;10:1129. doi: 10.3389/fphar.2019.01129. eCollection 2019.

4.

A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.

Kuo J, Bobardt M, Chatterji U, Mayo PR, Trepanier DJ, Foster RT, Gallay P, Ure DR.

J Pharmacol Exp Ther. 2019 Nov;371(2):231-241. doi: 10.1124/jpet.119.261099. Epub 2019 Aug 12.

5.

The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice.

Gallay P, Ure D, Bobardt M, Chatterji U, Ou J, Trepanier D, Foster R.

PLoS One. 2019 Jun 10;14(6):e0217433. doi: 10.1371/journal.pone.0217433. eCollection 2019.

6.

The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate.

Bobardt M, Kuo J, Chatterji U, Chanda S, Little SJ, Wiedemann N, Vuagniaux G, Gallay PA.

PLoS One. 2019 Feb 4;14(2):e0211746. doi: 10.1371/journal.pone.0211746. eCollection 2019.

7.

Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice.

Gallay PA, Chatterji U, Kirchhoff A, Gandarilla A, Pyles RB, Baum MM, Moss JA.

Open Virol J. 2018 Feb 28;12:1-13. doi: 10.2174/1874357901812010001. eCollection 2018.

8.

Coronaviruses and arteriviruses display striking differences in their cyclophilin A-dependence during replication in cell culture.

de Wilde AH, Zevenhoven-Dobbe JC, Beugeling C, Chatterji U, de Jong D, Gallay P, Szuhai K, Posthuma CC, Snijder EJ.

Virology. 2018 Apr;517:148-156. doi: 10.1016/j.virol.2017.11.022. Epub 2017 Dec 15.

9.

Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice.

Gallay PA, Chatterji U, Kirchhoff A, Gandarilla A, Gunawardana M, Pyles RB, Marzinke MA, Moss JA, Baum MM.

PLoS One. 2017 Sep 7;12(9):e0184303. doi: 10.1371/journal.pone.0184303. eCollection 2017.

10.

Systems Biology Reveals NS4B-Cyclophilin A Interaction: A New Target to Inhibit YFV Replication.

Vidotto A, Morais AT, Ribeiro MR, Pacca CC, Terzian AC, Gil LH, Mohana-Borges R, Gallay P, Nogueira ML.

J Proteome Res. 2017 Apr 7;16(4):1542-1555. doi: 10.1021/acs.jproteome.6b00933. Epub 2017 Mar 27.

PMID:
28317380
11.

Glucose biosensor based on functionalized ZnO nanowire/graphite films dispersed on a Pt electrode.

Gallay P, Tosi E, Madrid R, Tirado M, Comedi D.

Nanotechnology. 2016 Oct 21;27(42):425501. doi: 10.1088/0957-4484/27/42/425501. Epub 2016 Sep 13.

PMID:
27622391
12.

Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection.

Chatterji U, Bobardt M, Schaffer L, Wood M, Gallay PA.

PLoS One. 2016 Jul 21;11(7):e0159511. doi: 10.1371/journal.pone.0159511. eCollection 2016.

13.

Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175.

Gallay PA, Chatterji U, Bobardt MD, Long Z, Zhang S, Su Z.

PLoS One. 2016 Apr 22;11(4):e0152036. doi: 10.1371/journal.pone.0152036. eCollection 2016.

14.

C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus Challenge.

Veazey RS, Chatterji U, Bobardt M, Russell-Lodrigue KE, Li J, Wang X, Gallay PA.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):693-8. doi: 10.1128/AAC.01925-15. Print 2016 Jan.

15.

The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.

Gallay PA, Bobardt MD, Chatterji U, Trepanier DJ, Ure D, Ordonez C, Foster R.

PLoS One. 2015 Aug 11;10(8):e0134707. doi: 10.1371/journal.pone.0134707. eCollection 2015.

16.

Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories.

Chatterji U, Bobardt M, Tai A, Wood M, Gallay PA.

Antimicrob Agents Chemother. 2015 May;59(5):2496-507. doi: 10.1128/AAC.04958-14. Epub 2015 Feb 9.

17.

Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection.

Hansson MJ, Moss SJ, Bobardt M, Chatterji U, Coates N, Garcia-Rivera JA, Elmér E, Kendrew S, Leyssen P, Neyts J, Nur-E-Alam M, Warneck T, Wilkinson B, Gallay P, Gregory MA.

Chem Biol. 2015 Feb 19;22(2):285-92. doi: 10.1016/j.chembiol.2014.10.023. Epub 2015 Jan 22.

18.

The role of immunophilins in viral infection.

Hopkins S, Gallay PA.

Biochim Biophys Acta. 2015 Oct;1850(10):2103-10. doi: 10.1016/j.bbagen.2014.11.011. Epub 2014 Nov 18.

19.

Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production.

Phillips S, Chokshi S, Chatterji U, Riva A, Bobardt M, Williams R, Gallay P, Naoumov NV.

Gastroenterology. 2015 Feb;148(2):403-14.e7. doi: 10.1053/j.gastro.2014.10.004. Epub 2014 Oct 8.

PMID:
25305505
20.

Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.

Lim PJ, Gallay PA.

Curr Opin Virol. 2014 Oct;8:30-7. doi: 10.1016/j.coviro.2014.04.012. Epub 2014 May 27. Review.

21.

Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells.

Bobardt M, Chatterji U, Lim P, Gawlik K, Gallay P.

Open Virol J. 2014 Mar 7;8:1-8. doi: 10.2174/1874357901408010001. eCollection 2014.

22.

The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.

Chatterji U, Garcia-Rivera JA, Baugh J, Gawlik K, Wong KA, Zhong W, Brass CA, Naoumov NV, Gallay PA.

Antimicrob Agents Chemother. 2014 Jun;58(6):3327-34. doi: 10.1128/AAC.00016-14. Epub 2014 Mar 31.

23.

HCV core protein and virus assembly: what we know without structures.

Gawlik K, Gallay PA.

Immunol Res. 2014 Oct;60(1):1-10. doi: 10.1007/s12026-014-8494-3. Review.

24.

HCV core residues critical for infectivity are also involved in core-NS5A complex formation.

Gawlik K, Baugh J, Chatterji U, Lim PJ, Bobardt MD, Gallay PA.

PLoS One. 2014 Feb 12;9(2):e88866. doi: 10.1371/journal.pone.0088866. eCollection 2014.

25.

Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.

Chamoun-Emanuelli AM, Bobardt M, Moncla B, Mankowski MK, Ptak RG, Gallay P, Chen Z.

Antimicrob Agents Chemother. 2014;58(2):687-97. doi: 10.1128/AAC.02000-13. Epub 2013 Nov 11.

26.

Host-targeting agents in the treatment of hepatitis C: a beginning and an end?

Baugh JM, Garcia-Rivera JA, Gallay PA.

Antiviral Res. 2013 Nov;100(2):555-61. doi: 10.1016/j.antiviral.2013.09.020. Epub 2013 Sep 30. Review.

27.

Curing a viral infection by targeting the host: the example of cyclophilin inhibitors.

Lin K, Gallay P.

Antiviral Res. 2013 Jul;99(1):68-77. doi: 10.1016/j.antiviral.2013.03.020. Epub 2013 Apr 8. Review.

28.

Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms.

Gallay PA, Ptak RG, Bobardt MD, Dumont JM, Vuagniaux G, Rosenwirth B.

Viruses. 2013 Mar 22;5(3):981-97. doi: 10.3390/v5030981.

29.

Profile of alisporivir and its potential in the treatment of hepatitis C.

Gallay PA, Lin K.

Drug Des Devel Ther. 2013;7:105-15. doi: 10.2147/DDDT.S30946. Epub 2013 Feb 15. Review.

30.

Development of a flow cytometry live cell assay for the screening of inhibitors of hepatitis C virus (HCV) replication.

Garcia-Rivera JA, Lin K, Hopkins S, Gregory MA, Wilkinson B, Gallay PA.

Open Virol J. 2012;6:97-102. doi: 10.2174/1874357901206010097. Epub 2012 Nov 26.

31.

Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection.

Hopkins S, Gallay P.

Viruses. 2012 Oct 29;4(11):2558-77. doi: 10.3390/v4112558. Review.

32.

Cyclophilin involvement in the replication of hepatitis C virus and other viruses.

Baugh J, Gallay P.

Biol Chem. 2012 Jul;393(7):579-87. doi: 10.1515/hsz-2012-0151. Review.

33.

HCV NS5A and IRF9 compete for CypA binding.

Bobardt M, Hopkins S, Baugh J, Chatterji U, Hernandez F, Hiscott J, Sluder A, Lin K, Gallay PA.

J Hepatol. 2013 Jan;58(1):16-23. doi: 10.1016/j.jhep.2012.08.007. Epub 2012 Aug 15.

34.

Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.

Garcia-Rivera JA, Bobardt M, Chatterji U, Hopkins S, Gregory MA, Wilkinson B, Lin K, Gallay PA.

Antimicrob Agents Chemother. 2012 Oct;56(10):5113-21. doi: 10.1128/AAC.00919-12. Epub 2012 Jul 16.

35.

Correlation between NS5A dimerization and hepatitis C virus replication.

Lim PJ, Chatterji U, Cordek D, Sharma SD, Garcia-Rivera JA, Cameron CE, Lin K, Targett-Adams P, Gallay PA.

J Biol Chem. 2012 Aug 31;287(36):30861-73. doi: 10.1074/jbc.M112.376822. Epub 2012 Jul 16.

36.

Sustained local delivery of structurally diverse HIV-1 microbicides released from sublimation enthalpy controlled matrices.

Gunaseelan S, Gallay PA, Bobardt MD, Dezzutti CS, Esch T, Maskiewicz R.

Pharm Res. 2012 Nov;29(11):3156-68. doi: 10.1007/s11095-012-0811-8. Epub 2012 Jun 27. Erratum in: Pharm Res. 2013 Mar;30(3):911.

37.

The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes.

Hopkins S, Bobardt M, Chatterji U, Garcia-Rivera JA, Lim P, Gallay PA.

Antimicrob Agents Chemother. 2012 Jul;56(7):3888-97. doi: 10.1128/AAC.00693-12. Epub 2012 May 14.

38.

Development and evaluation of an enzyme-linked immunosorbent assay for dengue capsid.

Selvarajah S, Chatterji U, Kuhn R, Kinney R, Vasudevan SG, Gallay P.

Open Virol J. 2012;6:29-37. doi: 10.2174/1874357901206010029. Epub 2012 Mar 29.

39.

Sublimable C5A delivery provides sustained and prolonged anti-HIV microbicidal activities.

Maskiewicz R, Bobardt M, Chatterji U, Gunaseelan S, Dezzutti CS, Penin F, Gallay PA.

Antimicrob Agents Chemother. 2012 Jun;56(6):3336-43. doi: 10.1128/AAC.00186-12. Epub 2012 Mar 19.

40.

The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection.

Hopkins S, DiMassimo B, Rusnak P, Heuman D, Lalezari J, Sluder A, Scorneaux B, Mosier S, Kowalczyk P, Ribeill Y, Baugh J, Gallay P.

J Hepatol. 2012 Jul;57(1):47-54. doi: 10.1016/j.jhep.2012.02.024. Epub 2012 Mar 13.

PMID:
22425702
41.

Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents.

Gallay PA.

Immunol Res. 2012 Jun;52(3):200-10. doi: 10.1007/s12026-011-8263-5. Review.

42.

PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus.

Chamoun AM, Chockalingam K, Bobardt M, Simeon R, Chang J, Gallay P, Chen Z.

Antimicrob Agents Chemother. 2012 Feb;56(2):672-81. doi: 10.1128/AAC.05722-11. Epub 2011 Nov 14.

43.

[Distal coronary thrombosis during L-asparaginase treatment for an acute lymphoblastic leukaemia].

Fraison JB, Calvet P, Domnisoru I, Altamiranda S, Vernhet-Kovacsik H, Saad A, Gallay P, Reny JL, Berdague P.

Ann Cardiol Angeiol (Paris). 2012 Aug;61(4):303-5. doi: 10.1016/j.ancard.2011.04.005. Epub 2011 May 10. French.

PMID:
21663890
44.

One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.

Denton PW, Othieno F, Martinez-Torres F, Zou W, Krisko JF, Fleming E, Zein S, Powell DA, Wahl A, Kwak YT, Welch BD, Kay MS, Payne DA, Gallay P, Appella E, Estes JD, Lu M, Garcia JV.

J Virol. 2011 Aug;85(15):7582-93. doi: 10.1128/JVI.00537-11. Epub 2011 May 18.

45.

Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner.

Foster TL, Gallay P, Stonehouse NJ, Harris M.

J Virol. 2011 Jul;85(14):7460-4. doi: 10.1128/JVI.00393-11. Epub 2011 May 18.

46.

HSV neutralization by the microbicidal candidate C5A.

de Witte L, Bobardt MD, Chatterji U, van Loenen FB, Verjans GM, Geijtenbeek TB, Gallay PA.

PLoS One. 2011 May 6;6(5):e18917. doi: 10.1371/journal.pone.0018917.

47.

Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family.

Gregory MA, Bobardt M, Obeid S, Chatterji U, Coates NJ, Foster T, Gallay P, Leyssen P, Moss SJ, Neyts J, Nur-e-Alam M, Paeshuyse J, Piraee M, Suthar D, Warneck T, Zhang MQ, Wilkinson B.

Antimicrob Agents Chemother. 2011 May;55(5):1975-81. doi: 10.1128/AAC.01627-10. Epub 2011 Mar 7.

48.

DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.

Coelmont L, Hanoulle X, Chatterji U, Berger C, Snoeck J, Bobardt M, Lim P, Vliegen I, Paeshuyse J, Vuagniaux G, Vandamme AM, Bartenschlager R, Gallay P, Lippens G, Neyts J.

PLoS One. 2010 Oct 27;5(10):e13687. doi: 10.1371/journal.pone.0013687.

49.

Cyclophilin inhibitors for the treatment of HCV infection.

Fischer G, Gallay P, Hopkins S.

Curr Opin Investig Drugs. 2010 Aug;11(8):911-8. Review.

PMID:
20721833
50.

HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors.

Chatterji U, Lim P, Bobardt MD, Wieland S, Cordek DG, Vuagniaux G, Chisari F, Cameron CE, Targett-Adams P, Parkinson T, Gallay PA.

J Hepatol. 2010 Jul;53(1):50-6. doi: 10.1016/j.jhep.2010.01.041. Epub 2010 Apr 3.

Supplemental Content

Loading ...
Support Center